The Duke Clinical Research Institute (DCRI) has been chosen as the Clinical Trials Data Coordinating Center for the US National Institutes of Health’s (NIH) large-scale national research studies for long Covid treatment.
As the data coordinating centre, the institute will collaborate with the Administrative Coordinating Center of the study, RTI International, to expedite the trial process.
Go deeper with GlobalData
They will also work on managing the programme-wide infrastructure of the study, set up a patient registry and initiate prevention and therapeutic multi-intervention studies at the same time in adults and children.
The data coordinating centre is part of the NIH Researching COVID to Enhance Recovery (RECOVER) initiative.
It will support efforts across other current Covid-19 research projects such as the NIH-funded Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) studies and the RECOVER Consortium.
See Also:
This will offer researchers and people the opportunity to participate in long Covid studies and aid in advancing science on the disease’s effects on health.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSince the Covid-19 pandemic onset in 2020, the DCRI has taken the lead or took part in over 13 Covid-19-associated awards.
It also led projects to lower virus spread in schools, improve vaccine safety, extend access to testing in underserved communities and understand the pandemic’s effects on health care workers.
Furthermore, the institute is collaborating with the NIH to lead trials that analyse repurposed therapies to treat mild or moderate Covid-19 patients.
The DCRI is also leading studies to assess if immune modulators can hinder overactive immune response in moderate and severe Covid-19 cases.
DCRI executive director Adrian Hernandez said: “From the onset of the pandemic, the DCRI has been at the forefront of Covid-19 research.
“We are excited to apply our expertise in leading large-scale research programmes to find much needed answers to predict, prevent, and treat long Covid.”
